162 related articles for article (PubMed ID: 25339032)
1. DOX-MTX-NPs augment p53 mRNA expression in OSCC model in rat: effects of IV and oral routes.
Abbasi MM; Khiavi MM; Monfaredan A; Hamishehkar H; Seidi K; Jahanban-Esfahlan R
Asian Pac J Cancer Prev; 2014; 15(19):8377-82. PubMed ID: 25339032
[TBL] [Abstract][Full Text] [Related]
2. Novel DOX-MTX nanoparticles improve oral SCC clinical outcome by down regulation of lymph dissemination factor VEGF-C expression in vivo: oral and IV modalities.
Abbasi MM; Monfaredan A; Hamishehkar H; Seidi K; Jahanban- Esfahlan R
Asian Pac J Cancer Prev; 2014; 15(15):6227-32. PubMed ID: 25124602
[TBL] [Abstract][Full Text] [Related]
3. New formulated "DOX-MTX-loaded nanoparticles" down- regulate HER2 gene expression and improve the clinical outcome in OSCCs model in rat: the effect of IV and oral modalities.
Abbasi MM; Monfaredan A; Hamishehkar H; Jahanban-Esfahlan R
Asian Pac J Cancer Prev; 2014; 15(21):9355-60. PubMed ID: 25422224
[TBL] [Abstract][Full Text] [Related]
4. Oral and IV dosages of doxorubicin-methotrexate loaded- nanoparticles inhibit progression of oral cancer by down- regulation of matrix Methaloproteinase 2 expression in vivo.
Abbasi MM; Jahanban-Esfahlan R; Monfaredan A; Seidi K; Hamishehkar H; Khiavi MM
Asian Pac J Cancer Prev; 2014; 15(24):10705-11. PubMed ID: 25605162
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Blood Parameters, Cardiac and Liver Enzymes in Oral Squamous Cell Carcinoma Following Treated with Injectable Doxorubicin-Loaded Nano-Particles.
Moradzadeh Khiavi M; Anvari E; Hamishehkar H; Abdal K
Asian Pac J Cancer Prev; 2019 Jul; 20(7):1973-1977. PubMed ID: 31350953
[TBL] [Abstract][Full Text] [Related]
6. Comparison of injectable doxorubicin & its nanodrug complex chemotherapy for the treatment of 4-nitroquinoline-1-oxide induced oral squamous cell carcinoma in rats.
Khiavi MM; Abdal K; Abbasi MM; Hamishehkar H; Aghbali AA; Salehi R; Sina M; Abdollahi B; Fotohi S
Indian J Med Res; 2017 Jan; 145(1):112-117. PubMed ID: 28574023
[TBL] [Abstract][Full Text] [Related]
7. Oral squamous cell carcinoma cells are resistant to doxorubicin through upregulation of miR‑221.
Du L; Ma S; Wen X; Chai J; Zhou D
Mol Med Rep; 2017 Sep; 16(3):2659-2667. PubMed ID: 28677788
[TBL] [Abstract][Full Text] [Related]
8. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings.
Khan Z; Tiwari RP; Mulherkar R; Sah NK; Prasad GB; Shrivastava BR; Bisen PS
Head Neck; 2009 Aug; 31(8):1039-48. PubMed ID: 19340865
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro.
Smolensky D; Rathore K; Bourn J; Cekanova M
J Cell Biochem; 2017 Sep; 118(9):2615-2624. PubMed ID: 27649518
[TBL] [Abstract][Full Text] [Related]
10. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment.
Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H
Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957
[TBL] [Abstract][Full Text] [Related]
11. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
12. Macrophage membrane-camouflaged pH-sensitive nanoparticles for targeted therapy of oral squamous cell carcinoma.
Yang L; Li H; Luo A; Zhang Y; Chen H; Zhu L; Yang D
J Nanobiotechnology; 2024 Apr; 22(1):168. PubMed ID: 38610015
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
14. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
15. RT-PCR amplification of RNA extracted from formalin-fixed, paraffin-embedded oral cancer sections: analysis of p53 pathway.
Tachibana M; Shinagawa Y; Kawamata H; Omotehara F; Horiuchi H; Ohkura Y; Kubota K; Imai Y; Fujibayashi T; Fujimori T
Anticancer Res; 2003; 23(3C):2891-6. PubMed ID: 12926130
[TBL] [Abstract][Full Text] [Related]
16. The role of p300 in the tumor progression of oral squamous cell carcinoma.
Cho YA; Hong JS; Choe EJ; Yoon HJ; Hong SD; Lee JI; Hong SP
J Oral Pathol Med; 2015 Mar; 44(3):185-92. PubMed ID: 25154636
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
Su L; Wang Y; Xiao M; Lin Y; Yu L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of KPNA2 inhibits autophagy in oral squamous cell carcinoma cell lines by blocking p53 nuclear translocation.
Lin F; Gao L; Su Z; Cao X; Zhan Y; Li Y; Zhang B
Oncol Rep; 2018 Jul; 40(1):179-194. PubMed ID: 29781035
[TBL] [Abstract][Full Text] [Related]
19. The Expression and Correlation of iNOS and p53 in Oral Squamous Cell Carcinoma.
Yang L; Wang Y; Guo L; Wang L; Chen W; Shi B
Biomed Res Int; 2015; 2015():637853. PubMed ID: 26523280
[TBL] [Abstract][Full Text] [Related]
20. The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate.
Ray L; Kumar P; Gupta KC
Biomaterials; 2013 Apr; 34(12):3064-76. PubMed ID: 23357370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
